Szeplaki, G. (Gabor)

Filtering

20231

Settings

Author search.filters.isAuthorOfPublication.0d29e1b0-c844-4eb3-a93a-c44915c7c223

Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation in the MANIFEST-17K study
    (Springer Nature, 2023) Ekanem, E. (Emmanuel); Neuzil, P. (Petr); Reichlin, T. (Tobias); Kautzner, J. (Joseph); van-der-Voort, P. (Pepijn); Jais, P. (Pierre); Chierchia, G. (Gian-Battista); Bulava, A. (Alan); Blaauw, Y. (Yuri); Skala, T. (Tomas); Fiala, M. (Martin); Duytschaever, M. (Mattias); Szeplaki, G. (Gabor); Schmidt, B. (Boris); Massoullie, G. (Grégoire); Neven, K. (Kars); Venard, O. T. (Olivier Thomas); Vijgen, J. (Jörgen); Gandjbakhch, E. (Estelle); Scherr, D. (Daniel); Johannessen, A. (Ane); Keane, D. (David); Boveda, S. (Serge); Maury, P. (Philippe); Garcia-Bolao, I. (Ignacio)
    Pulsed field ablation (PFA) is an emerging technology for the treatment of atrial fibrillation (AF), for which pre-clinical and early-stage clinical data are suggestive of some degree of preferentiality to myocardial tissue ablation without damage to adjacent structures. Here in the MANIFEST-17K study we assessed the safety of PFA by studying the post-approval use of this treatment modality. Of the 116 centers performing post-approval PFA with a pentaspline catheter, data were received from 106 centers (91.4% participation) regarding 17,642 patients undergoing PFA (mean age 64, 34.7% female, 57.8% paroxysmal AF and 35.2% persistent AF). No esophageal complications, pulmonary vein stenosis or persistent phrenic palsy was reported (transient palsy was reported in 0.06% of patients; 11 of 17,642). Major complications, reported for ~1% of patients (173 of 17,642), were pericardial tamponade (0.36%; 63 of 17,642) and vascular events (0.30%; 53 of 17,642). Stroke was rare (0.12%; 22 of 17,642) and death was even rarer (0.03%; 5 of 17,642). Unexpected complications of PFA were coronary arterial spasm in 0.14% of patients (25 of 17,642) and hemolysis-related acute renal failure necessitating hemodialysis in 0.03% of patients (5 of 17,642). Taken together, these data indicate that PFA demonstrates a favorable safety profile by avoiding much of the collateral damage seen with conventional thermal ablation. PFA has the potential to be transformative for the management of patients with AF.